Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Edap Tms SA    EDAP

EDAP TMS SA (EDAP)
My previous session
Most popular
SummaryQuotesChartsNewsCompany 
News SummaryMost relevantAll newsOfficial PublicationsSector news
The feature you requested does not exist. However, we suggest the following feature:

EDAP TMS SA : EDAP Announces the Purchase of Focal One® HIFU by Maimonides Medical Center, Brooklyn, NY

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/18/2019 | 08:01am EST

Maimonides Medical Center to Become the First Hospital on the East Coast of the US to Acquire Focal One Technology and Offer the World's Most Advanced HIFU Prostate Treatment

LYON, France - January 18, 2019 - EDAP TMS SA (Nasdaq: EDAP) today announced that Brooklyn, New York's Maimonides Medical Center has become the second hospital in the United States, and the first on the East Coast, to acquire the groundbreaking Focal One high intensity focused ultrasound (HIFU) technology, the world's most advanced non-invasive prostate ablation device. Maimonides Medical Center urologists were recently trained on the use of Focal One and will begin to schedule the outpatient treatments for eligible patients with localized prostate cancer in February 2019.

"I have long been convinced that focal therapy is potentially an ideal option for some men with prostate cancer, in much the same way lumpectomy has replaced complete ablation of the breast for many women with breast cancer," said David A. Silver, MD, Chief of urology at Maimonides Medical Center, and Director of the Maimonides Prostate Center. "Shortly after Focal One was cleared by the FDA, I saw HIFU treatments in Montreal where physicians have treated more than 100 patients. It was clear to me that Focal One was the perfect tool to achieve a focal ablation, meaning we can treat the cancer, preserve the prostate, and enable our patients to maintain their quality of life. The move from whole-gland therapy to focal therapy represents a real paradigm shift in the way we approach prostate cancer."

Implementing Focal One is consistent with the hospital's goal of continuously enriching and expanding its services with the most leading-edge technology available to meet the needs of its patients.

"At Maimonides Medical Center, we're delighted to be the first on the East Coast to acquire this breakthrough technology," said Kenneth Gibbs, president and CEO of Maimonides. "When our cancer experts told us that this is a game-changer for many of our prostate cancer patients, we did not hesitate. This precision technology clearly places our program among the most advanced in the world-right here in Brooklyn, New York."

"We are extremely enthusiastic to count Maimonides Medical Center as the first to embrace our Focal One technology in the Eastern US. Shortly after the first US device sold a few weeks ago, this new Focal One sale confirms the appeal our technology represents for the US market," commented Marc Oczachowski, Chief Executive Officer of EDAP TMS.

About the Maimonides Medical Center
Maimonides Medical Center is nationally recognized for clinical excellence across all major specialties. Our accomplished physicians are known for innovation and strengthening our teaching and research programs. With 711 beds, the Medical Center is dedicated to bringing patients the most advanced care available-anywhere. Maimonides continues to grow in response to evolving models of care and the needs of our communities, and is home to Brooklyn's only full-service Cancer Center and its only Children's Hospital. According to the federal government, Maimonides is a "Top 10" hospital nationally for patient survival rates. To learn more about the clinical programs at Maimonides, please visit www.maimonidesmed.org.

About EDAP TMS
A recognized leader in the global therapeutic ultrasound market for almost 40 years, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally-invasive medical devices for urology using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in 2013 in Europe and in 2018 in the US as the answer to all requirements for ideal prostate tissue ablation and a complement to the existing FDA cleared Ablatherm® Robotic HIFU and Ablatherm® Fusion. As a pioneer and key player in the field of extracorporeal shock wave lithotripsy (ESWL), EDAP TMS exclusively utilizes the latest generation of shock wave source in its Sonolith® range of ESWL systems. For more information on the Company, please visit www.edap-tms.com, and us.hifu-prostate.com.

Forward-Looking Statements
In addition to historical information, this press release may contain forward-looking statements. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy device. Factors that may cause such a difference also may include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F.

Investor Contact
Jeremy Feffer
LifeSci Advisors, LLC
212-915-2568
jeremy@lifesciadvisors.com

Company Contact
Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 50
bconfort@edap-tms.com

Contact PR Media
Cindi Goodsell
510-635-4150
cgoodsell@hardenpartners.com

EDAP-TMS_300dpi_20160111.jpg

Source: EDAP TMS S.A.

2019 GlobeNewswire, Inc., source Press Releases

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on EDAP TMS SA
01/18EDAP TMS SA : EDAP Announces the Purchase of Focal One® HIFU by Maimonides Medic..
AQ
01/14EDAP TMS SA : EDAP Announces Sales of Two Additional Focal One® Devices in Brazi..
GL
01/03ADRs End Lower; CRH, Credit Suisse and EDAP Trade Actively
DJ
01/03EDAP TMS SA : John Wayne Cancer Institute First US Medical Center to Acquire EDA..
AQ
2018EDAP TMS SA : EDAP Announces Expiration of Second and Final Tranche of Outstandi..
GL
2018EDAP TMS SA : EDAP to Present a Corporate Update at the 30th Annual Piper Jaffra..
GL
2018EDAP TMS SA : EDAP Reports 2018 Third Quarter Results
GL
2018EDAP TMS SA : EDAP TMS SA to Announce Third Quarter 2018 Financial Results on We..
AQ
2018EDAP TMS SA : Urologic Oncologists from Top US Teaching Hospitals Gather in Mont..
GL
2018EDAP TMS SA : EDAP Announces Expiration of Tranche of Outstanding Warrants
AQ
More news
Chart EDAP TMS SA
Duration : Period :
Edap Tms SA Technical Analysis Chart | MarketScreener
Full-screen chart
Sector and Competitors
1st jan.Capitalization (M$)
EDAP TMS SA45.41%0
THERMO FISHER SCIENTIFIC7.90%96 900
DANAHER CORPORATION2.92%74 583
INTUITIVE SURGICAL10.66%61 300
BOSTON SCIENTIFIC CORPORATION5.43%51 560
ILLUMINA0.79%44 632